Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Sees Significant Growth in Short Interest

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the target of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 80,248 shares, a growth of 114.6% from the April 30th total of 37,392 shares. Based on an average daily volume of 114,555 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.2% of the company’s stock are short sold.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a report on Monday, May 18th. UBS Group lifted their price target on Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. Guggenheim lifted their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Nanobiotix has a consensus rating of “Moderate Buy” and an average target price of $26.67.

Institutional Trading of Nanobiotix

Institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada grew its stake in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares in the last quarter. Optiver Holding B.V. purchased a new stake in Nanobiotix during the 3rd quarter valued at about $101,000. Marshall Wace LLP purchased a new stake in Nanobiotix during the 4th quarter valued at about $220,000. Finally, Millennium Management LLC purchased a new stake in Nanobiotix during the 4th quarter valued at about $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Stock Down 0.0%

Shares of NBTX stock traded down $0.01 on Friday, reaching $40.40. 39,156 shares of the company were exchanged, compared to its average volume of 88,675. The business has a 50-day moving average price of $36.64 and a 200 day moving average price of $28.39. Nanobiotix has a 1 year low of $4.06 and a 1 year high of $57.14.

Nanobiotix (NASDAQ:NBTX) last released its earnings results on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $3.42 million for the quarter. Equities analysts forecast that Nanobiotix will post 0.19 earnings per share for the current fiscal year.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.